We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology business with stocks listed in the US. It opened the day at US$186.24 after a previous close of US$187.1. During the day the price has varied from a low of USD184.78 to a high of USD188.535. The latest price was USD188.3 (25 minute delay). Vertex Pharmaceuticals Incorporated is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| Open | US$186.24 |
|---|---|
| High | US$188.535 |
| Low | US$184.78 |
| Close | US$188.3 |
| Previous close | US$187.1 |
| Change | US$1.2 |
| Change % | 0.6414% |
| Volume | 2,214,404 |
| 52-week range | US$176.36 - US$242.99 |
|---|---|
| 50-day moving average | US$184.4706 |
| 200-day moving average | US$199.6222 |
| Target price | US$258.45 |
| PE ratio | 24.1951 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$7.585 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $188.3
| 1 week (2021-10-18) | 4.15% |
|---|---|
| 1 month (2021-09-24) | 2.55% |
| 3 months (2021-07-26) | -5.34% |
| 6 months (2021-04-26) | -13.21% |
| 1 year (2020-10-26) | -9.10% |
|---|---|
| 2 years (2019-10-25) | -3.18% |
| 3 years (2018-10-26) | 11.10% |
| 5 years (2016-10-26) | 139.23% |
Valuing Vertex Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Vertex Pharmaceuticals Incorporated shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Vertex Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2852. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.4 billion (£1.7 billion).
The EBITDA is a measure of a Vertex Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$6.7 billion |
|---|---|
| Operating margin TTM | 33.93% |
| Gross profit TTM | US$3.6 billion |
| Return on assets TTM | 12.63% |
| Return on equity TTM | 23.83% |
| Profit margin | 29.8% |
| Book value | 35.492 |
| Market capitalisation | US$48.5 billion |
TTM: trailing 12 months
There are currently 5.1 million Vertex Pharmaceuticals Incorporated shares held short by investors – that's known as Vertex Pharmaceuticals Incorporated's "short interest". This figure is 2.2% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting Vertex Pharmaceuticals Incorporated shares can be evaluated.
Vertex Pharmaceuticals Incorporated's "short interest ratio" (SIR) is the quantity of Vertex Pharmaceuticals Incorporated shares currently shorted divided by the average quantity of Vertex Pharmaceuticals Incorporated shares traded daily (recently around 1.4 million). Vertex Pharmaceuticals Incorporated's SIR currently stands at 3.72. In other words for every 100,000 Vertex Pharmaceuticals Incorporated shares traded daily on the market, roughly 3720 shares are currently held short.
However Vertex Pharmaceuticals Incorporated's short interest can also be evaluated against the total number of Vertex Pharmaceuticals Incorporated shares, or, against the total number of tradable Vertex Pharmaceuticals Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vertex Pharmaceuticals Incorporated's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vertex Pharmaceuticals Incorporated shares in existence, roughly 20 shares are currently held short) or 0.0196% of the tradable shares (for every 100,000 tradable Vertex Pharmaceuticals Incorporated shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vertex Pharmaceuticals Incorporated.
Find out more about how you can short Vertex Pharmaceuticals Incorporated stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals Incorporated.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals Incorporated's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals Incorporated is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.65/100
Vertex Pharmaceuticals Incorporated's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.22/100
Vertex Pharmaceuticals Incorporated's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.46/100
Vertex Pharmaceuticals Incorporated's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals Incorporated scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals Incorporated has, for the most part, managed to keep its nose clean.
Vertex Pharmaceuticals Incorporated was last rated for ESG on: 2019-01-01.
| Total ESG score | 30.84 |
|---|---|
| Total ESG percentile | 44 |
| Environmental score | 5.65 |
| Environmental score percentile | 8 |
| Social score | 24.22 |
| Social score percentile | 8 |
| Governance score | 12.46 |
| Governance score percentile | 8 |
| Level of controversy | 2 |
We're not expecting Vertex Pharmaceuticals Incorporated to pay a dividend over the next 12 months.
Vertex Pharmaceuticals Incorporated's shares were split on a 2:1 basis on 23 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals Incorporated shares which in turn could have impacted Vertex Pharmaceuticals Incorporated's share price.
Over the last 12 months, Vertex Pharmaceuticals Incorporated's shares have ranged in value from as little as US$176.36 up to US$242.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals Incorporated's is 0.6566. This would suggest that Vertex Pharmaceuticals Incorporated's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
Steps to owning and managing GQG Partners shares.
